This is my #1 ASX growth share to buy right now

I'm backing this ASX healthcare share as an exciting opportunity.

| More on:
A man in a business suit and a tie leans forward with an excited, wide-mouthed expression and holds up one finger to the camera as if indicating the number one.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Volpara is an ASX growth share delivering impressive strong double-digit revenue growth
  • It’s expecting further growth to come from multiple areas, including cross-selling software opportunities with existing customers
  • The company is expecting improved profits margins over the next year, which means the business could achieve breakeven

Volpara Health Technologies Ltd (ASX: VHT) shares look very appealing to me. At the current time, the company is the top ASX growth share I'd want in my portfolio.

Volpara describes its business as making software to "save families from cancer". It says healthcare providers use Volpara to "better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions". It's mainly focused on breast screening.

The ASX healthcare share recently announced its FY23 result which included a number of positives. These seem very promising for the ASX growth share's future. In my view, here are some of the main factors that make it attractive:

Strong revenue growth

Volpara reported its revenue rose by 34% to NZ$35 million in FY23.

The business said all three of its core products (analytics, patient hub/MRS, and risk pathways) experienced "strong revenue growth" of 30%, 33%, and 49% respectively.

The ASX healthcare share has set guidance for FY24 revenue in constant currency terms of between NZ$40 million and NZ$42 million. This would represent a rise of 15% to 20% compared to FY23.

Volpara also saw its average revenue per account (ARPA) grow by 30% in FY23. That represents the annual recurring revenue (ARR) divided by the total number of customers.

The ASX growth share's net revenue retention was 107% for the year. Not only did the business hang onto a very high percentage of its revenue from existing customers during the year, but it managed to add more revenue from those customers.

Market share and cross-selling potential

The ASX healthcare share has estimated one of its software products has been used in more than 40% of mammography/breast screening volumes in the United States.

Volpara noted a "significant" portion of its customers only use one Volpara product.

Management thinks this presents an "excellent opportunity" for the company to cross-sell additional products to its existing customer base.

The company is looking to provide customers with a unified Volpara experience, integrating its products seamlessly.

There are a number of positives for the ASX growth share which could suggest further revenue growth.

Tailwinds could help, according to Volpara. These include mandatory breast density reporting in the US, an ageing population resulting in more women moving into screening age, and an "increasing incidence of breast cancer".

The company is working on expanding in Europe, which could open up a large new market for the ASX healthcare share.

Volpara is also trying to grow its products into new market segments, including insurance and employers, while also launching new products to its existing market including more risk models.

Finally, its revenue could be boosted by expanding in imaging beyond breast screening, and in risk beyond cancer. It's also looking at leveraging artificial intelligence to create "new models for image analysis and interpretation".

Improving profit margin potential

While total revenue rose 34%, gross profit went up 36%, thanks to a 1.3% percentage point improvement to 92.5%. The net loss after tax improved 40% to NZ$9.8 million.

Volpara pointed to its overall operating expenses reaching stability, with large improvements in each of its four major cost categories.

Its high gross profit margin and improving revenue can help deliver improving margins. The ASX healthcare share says its earnings before interest, tax, depreciation and amortisation (EBITDA) in FY24 could be breakeven.

I think the ASX growth share will demonstrate its rapidly improving profit margins over the next couple of years, which could really impress the market. Since the start of the year, the Volpara share price has risen 37%, as we can see on the chart below.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Volpara Health Technologies. The Motley Fool Australia has positions in and has recommended Volpara Health Technologies. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

Man ponders a receipt as he looks at his laptop.
Opinions

3 reasons why the Xero share price could be a strong buy

This stock has all the hallmarks of a long-term winner.

Read more »

Happy miner giving ok sign in front of a mine.
Opinions

Which ASX 200 stock offers 'material upside' amid continuing uncertainty over US tariffs?

Blackwattle Investment has identified one ASX 200 large-cap stock that is thriving on the uncertainty.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Financial Shares

2 rising ASX financial shares with 'meaningful upside' still left: fundie

Financials outperformed every other sector in FY25, but there are still buying opportunities left, say these experts.

Read more »

A businessman hugs his computer and smiles.
Opinions

If I could only own one ASX 200 share for the rest of my life, it'd be this one

This is one stock I expect to own forever.

Read more »

Man ponders a receipt as he looks at his laptop.
Technology Shares

Brokers rerate 3 leading ASX 200 tech stocks

Experts reveal their ratings on the ASX 200 tech sector's three biggest companies.

Read more »

Person holding a blue chip.
Opinions

Buy alert! 2 ASX 200 blue-chip shares worth a look now: expert

Dylan Evans from Catapult Wealth has identified two blue-chip shares that he thinks are good buys today.

Read more »

Two happy woman on a couch looking at a tablet.
Opinions

Why I'm excited to see the results of these ASX 200 shares

These stocks could reveal very interesting insights.

Read more »

Young male investor smiling looking at laptop as the share price of ASX ETF CRYP goes higher today
Opinions

Why I just bought this 5.2%-yielding ASX dividend stock and plan to buy even more

This business is one of my favourites for dividends and total returns.

Read more »